| Literature DB >> 29958801 |
Jinyang Li1, Katelyn T Byrne2, Fangxue Yan1, Taiji Yamazoe1, Zeyu Chen3, Timour Baslan4, Lee P Richman1, Jeffrey H Lin1, Yu H Sun5, Andrew J Rech6, David Balli1, Ceire A Hay7, Yogev Sela1, Allyson J Merrell1, Shannon M Liudahl8, Naomi Gordon1, Robert J Norgard1, Salina Yuan1, Sixiang Yu1, Timothy Chao1, Shuai Ye1, T S Karin Eisinger-Mathason1, Robert B Faryabi9, John W Tobias10, Scott W Lowe11, Lisa M Coussens8, E John Wherry12, Robert H Vonderheide13, Ben Z Stanger14.
Abstract
The biological and functional heterogeneity between tumors-both across and within cancer types-poses a challenge for immunotherapy. To understand the factors underlying tumor immune heterogeneity and immunotherapy sensitivity, we established a library of congenic tumor cell clones from an autochthonous mouse model of pancreatic adenocarcinoma. These clones generated tumors that recapitulated T cell-inflamed and non-T-cell-inflamed tumor microenvironments upon implantation in immunocompetent mice, with distinct patterns of infiltration by immune cell subsets. Co-injecting tumor cell clones revealed the non-T-cell-inflamed phenotype is dominant and that both quantitative and qualitative features of intratumoral CD8+ T cells determine response to therapy. Transcriptomic and epigenetic analyses revealed tumor-cell-intrinsic production of the chemokine CXCL1 as a determinant of the non-T-cell-inflamed microenvironment, and ablation of CXCL1 promoted T cell infiltration and sensitivity to a combination immunotherapy regimen. Thus, tumor cell-intrinsic factors shape the tumor immune microenvironment and influence the outcome of immunotherapy.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29958801 PMCID: PMC6707727 DOI: 10.1016/j.immuni.2018.06.006
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 43.474